HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the ...
HUTCHMED announces new data from studies of compounds to be presented at 2024 WCLC and ESMO Congresses. Key findings include positive results from the FLOWERS study, showing deeper and more durable response with osimertinib plus savolitinib in EGFRm, MET-aberrant advanced NSCLC patients compared to osimertinib monotherapy.
Highlighted Terms
Related News
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the ...
HUTCHMED announces new data from studies of compounds to be presented at 2024 WCLC and ESMO Congresses. Key findings include positive results from the FLOWERS study, showing deeper and more durable response with osimertinib plus savolitinib in EGFRm, MET-aberrant advanced NSCLC patients compared to osimertinib monotherapy.